E
EVLO

Ergoteles’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Ergoteles’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,371
Closed -$57K – 2073
2022
Q3 		$57K Sell
1,371
-13,845
-91% -$633K ﹤0.01% 1433
2022
Q2 		$642K Buy
+15,216
New +$705K 0.02% 726

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's EVLO Position: Q4 2022 in Review

Ergoteles sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2022, closing a stake of 1,371 shares — an estimated $57K sold.

Ergoteles first reported a position in EVLO in Q2 2022 and held it in 2 quarters. The position peaked at $642K in Q2 2022. 44 funds tracked by Wall St. Rank hold EVLO as of Q4 2022.

  • Ergoteles reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 1,371 Evelo Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $57K.
  • Ergoteles first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Evelo Biosciences, Inc. Common Stock position peaked at $642K in Q2 2022.
  • 44 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.